DBVT Stock: DBV Technologies S.A. Stock Price, Analysis & Insights
Get live dbvt stock price $22.55, comprehensive DBV Technologies S.A. stock analysis, charts, news, and expert forecast. Real-time dbvt stock data and investment insights.
Loading chart...
Company Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Company Information
- CEO
- Daniel Tassé
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 106
Contact Information
- Address
- 177-181 Avenue Pierre Brossolette
- Country
- FR
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: -0.50) may provide portfolio stability
Business Model & Strategy
DBV Technologies S.A. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Daniel Tassé, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
DBV Technologies S.A. competes in the Biotechnology within the broader Healthcare. With 539.4 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, DBV Technologies S.A. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating DBV Technologies S.A. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for DBV Technologies S.A. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for DBV Technologies S.A.
- ⚠Investors should consider how DBV Technologies S.A. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
539.44M
P/E Ratio
-4.34
Beta
-0.50
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 539.44M market capitalization
- Trading Volume: 3.94M shares traded today
- Price Range: 52-week range of $2.74 - $26.18
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for DBV Technologies S.A.
DBV Technologies S.A. (DBVT) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 539.44M, the company represents a significant player in its market. The stock is currently trading at $22.55 with a positivedaily change of 25.42%.
The company's 106 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -4.34, beta of -0.50, and 52-week price range from $2.74 to $26.18when evaluating investment opportunities.
Why Invest in DBV Technologies S.A.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Daniel Tassé
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.